The solution to the medicinal cannabis problem

Ethical Issues in Chronic Pain Management

Volumn , Issue , 2016, Pages 165-194

  Russo, Ethan B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991749704     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (147)

1. ABC News, USA Today, Stanford Medical Center Poll. Broad experience with pain sparks search for relief. May 9 2005.
2. http://abcnews.go.com/images/Politics/979a1TheFightAgainstPain.pdf.
3. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112(3):299-306.
4. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(1):50-52.
5. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004; 10:425-433.
6. Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. Paper presented at British Pain Society, Edinburgh, Scotland, March 8-11, 2005.
7. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ''N of 1'' studies. Anesthesia 2004; 59:440-452.
8. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ. A multicenter, doubleblind, randomized, placebo-controlled trial of oromucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. Neurology 2005; 64(6 suppl 1):A374.
9. Rog DJ, Nurmiko T, Friede T, Young C. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology 2005; 65(6):812-819.
10. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10(4):434-441.
11. Wade DT, Makela PM, House H, Bateman C, Robson PJ. Long-term use of a cannabisbased medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. In press.
12. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17:18-26.
13. Joy JE, Watson SJ, Benson JA Jr. Marijuana and medicine: assessing the science base. Washington, DC: Institute of Medicine, 1999.
14. Mead A. International control of cannabis: changing attitudes. In: Guy GW, Whittle BA, Robson P, eds. Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press, 2004:369-426.
15. Russo EB. Handbook of Psychotropic Herbs: A Scientific Analysis of Herbal Remedies for Psychiatric Conditions. Binghamton, NY: Haworth Press, 2001.
16. Food and Drug Administration. Guidance for industry: botanical drug products. In: Services UDoHaH, ed. US Government. 2004:48.
17. http://www.fda.gov/cder/guidance/4592fnl.pdf.
18. Russo EB. The role of cannabis and cannabinoids in pain management. In: Cole BE, Boswell M, eds. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. Boca Raton, FL: CRC Press, 2006:823-844.
19. Russo EB. Cannabis in India: ancient lore and modern medicine. In: Mechoulam R, ed. Cannabinoids as Therapeutics. Basel, Switzerland: Birkhäuser Verlag, 2005:1-22.
20. Russo EB. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther 2001; 1(2):21-92.
21. Russo EB. History of cannabis as medicine. In: Guy GW, Whittle BA, Robson P, eds. Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press, 2004:1-16.
22. Mechoulam R. Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press, 1986.
23. Russo E. Cannabis treatments in obstetrics and gynecology: a historical review. J Cannabis Ther 2002; 2(3-4):5-35.
24. Riddle JM. Historical data as an aid in pharmaceutical prospecting and drug safety determination. J Altern Complement Med 1999; 5(2):195-201.
25. Randall RC. Muscle spasm, pain & marijuana therapy: testimony from federal and state court proceedings on marijuana's medical use in the treatment of multiple sclerosis, paralysis, and chronic pain. Washington, DC: Galen Press, 1991.
26. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. Rev. and expanded. New Haven: Yale University Press, 1997.
27. Last resorts and fundamental rights: the substantive due process implications of prohibitions on medical marijuana. Harv Law Rev 2005; 118(62):1985-2006.
28. Gostin LO. Medical marijuana, American federalism, and the Supreme Court. JAMA 2005; 294(7):842-844.
29. Okie S. Medical marijuana and the Supreme Court. N Engl J Med 2005; 353(7):648-651.
30. Janse A, Breekveldt-Postma N, Erkens J, Herings R. Medicinal cannabis in the Netherlands. Paper presented at International Association for Cannabis as Medicine, Leiden, Netherlands, September 9, 2005.
31. Déry L. Canadian Medical Marijuana Research Program: main purpose and accomplishments. Paper presented at International Association for Cannabis as Medicine, Leiden, Netherlands, September 9, 2005.
32. Sibbald B. New medicinal marijuana rules ease onus on physicians. CMAJ 2005; 173(5):473.
33. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319(2-3): R3-R4.
34. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998; 18(1):451-457.
35. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345(2):145-153.
36. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75(1):111-119.
37. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by the release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci 1999; 96(21):12198-12203.
38. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848(1-2):183-190.
39. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134(4):845-852.
40. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999; 289(2):859-867.
41. Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta (9)-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 2001; 297(1):121-127.
42. Cichewicz DL, Welch SP. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 2003; 305(3):812-817.
43. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 2004; 25(1-2):31-39.
44. Noyes R Jr., Baram DA. Cannabis analgesia. Compr Psychiatry 1974; 15(6):531-535.
45. Noyes R Jr., Brunk SF, Avery DAH, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18(1):84-89.
46. Noyes R Jr., Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15(2-3):139-143.
47. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004; 8(2):173-177.
48. Clermont-Gnamien S, Atlani S, Attal N, Le Mercier F, Guirimand F, Brasseur L. Utilization thérapeutique du delta-9-tétrahydrocannabinol (dronabinol) dans les douleurs neuropathiques réfractaires. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. Presse Med 2002; 31(39 pt 1): 1840-1845.
49. Rudich Z, Stinson J, Jeavons M, Brown SC. Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents. Pain Res Manag 2003; 8(4):221-224.
50. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460):253.
51. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998; 30(2):187-196.
52. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106(1-2):169-172.
53. Broom SL, Sufka KJ, Elsohly MA, Ross RA. Analgesic and reinforcing properties of delta9-THC-hemisuccinate in adjuvant-arthritic rats. J Cannabis Ther 2001; 1(3-4): 171-182.
54. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34(10):446-452.
55. Elsohly MA, Little TL Jr., Hikal A, Harland E, Stanford DF, Walker L. Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav 1991; 40(3):497-502.
56. Mattes RD, Engelman K, Shaw LM, Elsohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994; 49(1):187-195.
57. Challapalli PV, Stinchcomb AL. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm 2002; 241(2):329-339.
58. Brenneisen R. Pharmacokinetics. In: Grotenhermen F, Russo E, eds. Cannabis and Cannabinoids: Pharmacology, Toxicity and Therapeutic Potential. Binghamton, NY: Haworth Press, 2001.
59. Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev Respir Dis 1977; 115(1):57-65.
60. McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 2001; 1(3-4):103-132.
61. Miller J, Meuwsen I, ZumBrunnen T, de Vries M. A Phase I evaluation of pulmonary dronabinol administered via a pressurized metered dose inhaler in healthy volunteers. Paper presented at American Academy of Neurology, Miami Beach, FL, April 14, 2005.
62. British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers, 1997.
63. Grotenhermen F. Definitions and explanations. In: Grotenhermen F, Russo E, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Binghamton, NY: Haworth Press, 2001.
64. Notcutt W, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharmaceutical Sci 1997; 3:551-555.
65. Burstein SH. The therapeutic potential of ajulemic acid (CT3). In: Grotenhermen F, Russo E, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Binghamton, NY: Haworth Press, 2001.
66. Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Res 2000; 6(13):1339-1345.
67. Liu J, Li H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 2003; 63(5):983-992.
68. Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 2003; 65(4):649-655.
69. Dyson A, Peacock M, Chen A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 2005; 116(1-2):129-137.
70. Campbell FA, Tramber MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. BMJ 2001; 323(7 July):1-6.
71. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at International Association for Cannabis as Medicine, Leiden, Netherlands, September 9, 2005.
72. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005; 63(2):93-100.
73. Morgenstern H, Greenland S, Zhang Z-F, Cozen W, Mack TM, Tashkin DP. Marijuana use and cancers of the lung and upper aerodigestive tract: results of a case-control study. Paper presented at Symposium on the Cannabinoids, 2005:Clearwater, FL, June 26, 2005.
74. Roth MD. Marijuana and your heart. Nature 2005; 434(7 April):708-709.
75. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103(23):2805-2809.
76. Combemale P, Consort T, Denis-Thelis L, Estival JL, Dupin M, Kanitakis J. Cannabis arteritis. Br J Dermatol 2005; 152(1):166-169.
77. Zanocco V. Meningococcal cases linked by sharing joints. http://www.vch.ca/news/ docs/2005_04_07_mening_joints.pdf. Accessed April 8.
78. Dussy FE, Hamberg C, Luginbuhl M, Schwerzmann T, Briellmann TA. Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. Forensic Sci Int 2005; 149(1):3-10.
79. Grotenhermen F. Clinical pharmacokinetics of cannabinoids. J Cannabis Ther 2003; 3(1):3-51.
80. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16(5):276-282.
81. Gieringer D. Waterpipe study. Bull Multidisciplinary Assoc Psychedel Stud 1996; 6:59-63.
82. Gieringer D. Why marijuana smoke harm reduction? Bull Multidisciplinary Assoc Psychedel Stud 1996; 6(64-66).
83. Russo EB, Stortz M. An interview with Markus Storz: June 19, 2002. J Cannabis Ther 2003; 3(1):67-78.
84. Abrams DI, Vizoso H, Shade SB, Jay C, Kelly ME, Benowitz N. Vaporization as a smokeless cannabis delivery system: a pilot study. Paper presented at International Association of Cannabis as Medicine, Leiden, Netherlands, September 10, 2005.
85. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95(6):1308-1317.
86. Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther 2004; 4(1):7-27.
87. Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses 2006; 66(2):234-246.
88. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 2003; 362(9395):1517-1526.
89. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76(12):1664-1669.
90. Ernst G, Denke C, Reif M, Schnelle M, Hagmeister H. Standardized cannabis extract in the treatment of postherpetic neuralgia: a randomized, double-blind, placebocontrolled crossover study. Paper presented at International Association for Cannabis as Medicine, Leiden, Netherlands, September 9, 2005.
91. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104(5):1040-1046.
92. Potter D. Growth and morphology of medicinal cannabis. In: Guy GW, Whittle BA, Robson P, eds. Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press, 2004:17-54.
93. de Meijer E. The breeding of cannabis cultivars for pharmaceutical end uses. In: Guy GW, Whittle BA, Robson P, eds. Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press, 2004:55-70.
94. Guy GW, Robson P. A Phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK02125). J Cannabis Ther 2003; 3(4):121-152.
95. Carlini EA. The good and the bad effects of (±) trans-delta-9-tetrahydrocannabinol (Delta (9)-THC) on humans. Toxicon 2004; 44(4):461-467.
96. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ. A multicenter, doubleblind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. Paper presented at American Academy of Neurology, Miami Beach, FL, April 14, 2005.
97. Russo EB. Sativex cannabis based medicine maintains improvements in sleep quality in patients with multiple sclerosis and neuropathic pain. Paper presented at American Academy of Neurology, Miami Beach, FL, April 12, 2005.
98. Stott CG, Guy GW, Wright S, Whittle BA. The genotoxicology of Sativex. Paper presented at Conference on the Cannabinoids, Clearwater, FL, June, 2005.
99. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychotropic cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 2004; 308(3):838-845.
100. Lynch ME, Young J. Report on a case series of patients using medicinal marijuana marijuana for management of chronic pain under the Canadian Medical Marijuana Access Regulations. Paper presented at Symposium on the Cannabinoids, Clearwater, FL, 2005.
101. Janse AFC, Breekveldt-Postma NS, Erkens JA, Herings RMC. Medicinal gebruik van cannabis: PHARMO Instituut [Institute for Drug Outcomes Research]. April 2004.
102. Gorter RW, Butorac M, Cobian EP, van der Sluis W. Medical use of cannabis in the Netherlands. Neurology 2005; 64(5):917-919.
103. http://www.neurology.org/cgi/content/full/64/5/917/DC1.
104. Wachtel SR, ElSohly MA, Ross RA, Ambre J, de Wit H. Comparison of the subjective effects of delta9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002; 161:331-339.
105. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 2005; 16(5-6):487-496.
106. Wilkinson JD, Whalley BJ, Baker D, et al. Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol 2003; 55(12):1687-1694.
107. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 2001; 8(5):401-409.
108. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998; 353(1):23-31.
109. Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 1999; 16(2):131-143.
110. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76(3):245-250.
111. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol [letter]. J Clin Psychiatry 1995; 56(10):485-486.
112. Leweke FM, Koethe D, Gerth CW, et al. Cannabidiol as an antipsychotic: a double-blind, controlled clinical trial on cannabidiol vs. amisulphide in acute schizophrenia. Paper presented at Symposium on the Cannabinoids, Clearwater, FL, June 26, 2005.
113. Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 1998; 11(10):1209-1216.
114. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann NY Acad Sci 2000; 899:274-282.
115. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral antiarthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97(17):9561-9566.
116. Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Ther 2001; 1(3-4):183-205.
117. de Meijer EP, Bagatta M, Carboni A, et al. The inheritance of chemical phenotype in Cannabis sativa L. Genetics 2003; 163(1):335-346.
118. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF III. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 2000; 45(1):24-30.
119. Mehmedic Z, Martin J, Foster S, ElSohlyMA.Delta-9-THC and other cannabinoids content of confiscated marijuana: potency trends, 1993-2003. Paper presented at International Association of Cannabis as Medicine, Leiden, Netherlands, September 10, 2005.
120. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004.
121. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351(17):1707-1709.
122. Stott CG, Guy GW, Wright S, Whittle BA. The effects of cannabis extracts Tetranabinex & Nabidiolex on human cyclooxygenase (COX) activity. Paper presented at Symposium on the Cannabinoids, Clearwater, FL, June 27, 2005.
123. Wright S. GWMS001 and GWMS0106: maintenance of blinding. London: GW Pharmaceuticals, 2005.
124. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161(11):1967-1977.
125. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002; 97(6):621-632.
126. Samaha AN, Robinson TE. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 2005; 26(2):82-87.
127. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci 1976; 282:221-239.
128. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287(9):1123-1131.
129. Russo EB, Mathre ML, Byrne A, et al. Chronic cannabis use in the Compassionate Investigational New Drug Program: an examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther 2002; 2(1):3-57.
130. Fride E, Russo EB. Neuropsychiatry: Schizophrenia, depression, and anxiety. In: Onaivi E, Sugiura T, Di Marzo V, eds. Endocannabinoids: The Brain and Body's Marijuana and Beyond. Boca Raton, FL: Taylor & Francis, 2006:371-382.
131. Pope HG Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10):909-915.
132. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71(1):37-48.
133. Zuardi AW, Guimaraes FS. Cannabidiol as an anxiolytic and antipsychotic. In: Mathre ML, ed. Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. Jefferson, NC: McFarland, 1997:133-141.
134. Cabral G. Immune system. In: Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Binghamton, NY: Haworth Press, 2001:279-287.
135. Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 2005; 140(3):580-585.
136. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139:258-266.
137. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early morning behavior in young adults. J Clin Psychopharmacol 2004; 24(3):305-313.
138. Stott CG, Guy GW, Wright S, Whittle BA. The effects of cannabis extracts Tetranabinex and Nabidiolex on human cytochrome P450-mediated metabolism. Paper presented at Symposium on the Cannabinoids, Clearwater, FL, June 27, 2005.
139. Movig KL, Mathijssen MP, Nagel PH, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 2004; 36(4):631-636.
140. Hadorn D. A review of cannabis and driving skills. In: Guy GW, Whittle BA, Robson P, eds. Medicinal Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press, 2004:329-368.
141. Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004; 92(3): 294-303; quiz 303-295, 355.
142. Soderstrom CA, Dischinger PC, Kufera JA, Ho SM, Shepard A. Crash culpability relative to age, and sex for injured drivers using alcohol, marijuana or cocaine. Paper presented at Association for the Advancement of Automotive Medicine, Cambridge, MA, September 12-14, 2005.
143. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: DiMarzo V, ed. Cannabinoids. Dordrecht, Netherlands: Kluwer Academic Publishers, 2004.
144. http://www.solvaypharmaceuticals-us.com/static/wma/pdf/1/3/1/9/Marinol5000 124ERev52003.pdf.
145. http://www.bayerhealth.ca/display.cfm? Object_ID=272&Article_ID=121&expand Menu_ID=53&prevSubItem=5_52.
146. Pertwee RG. Cannabidiol as a potential medicine. In: Mechoulam R, ed. Cannabinoids as Therapeutics. Basel, Switzerland: Birkhäuser Verlag, 2005:47-65.
147. Grotenhermen F, Leson G, Berghaus G, et al. Developing Science-Based Per Se Limits for Driving Under the Influence of Cannabis (DUIC). Findings and Recommendations by an Expert Panel. Hü rth, Germany: Nova-Institut, 2005.